(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are NASDAQ TEST STOCK, Aurora Cannabis, and Canopy Growth.

The three biggest losers today are Yield10 Bioscience , FibroGen, and Identiv.

Winners today

1. NASDAQ TEST STOCK (ZVZZT) – 155.71%

NASDAQ ended the session with NASDAQ TEST STOCK rising 155.71% to $73.72 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ rose 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Yearly Top and Bottom Value

NASDAQ TEST STOCK’s stock is valued at $73.72 at 17:32 EST, way below its 52-week low of $12.13.

More news about NASDAQ TEST STOCK.

2. Aurora Cannabis (ACB) – 44.06%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

NYSE ended the session with Aurora Cannabis jumping 44.06% to $7.21 on Wednesday while NYSE jumped 0.22% to $18,146.64.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-58.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.67%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 225.18M for the twelve trailing months.

Sales Growth

Aurora Cannabis’s sales growth for the next quarter is 7%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 84.6% and 86.7%, respectively.

Moving Average

Aurora Cannabis’s worth is way above its 50-day moving average of $0.47 and way above its 200-day moving average of $0.54.

More news about Aurora Cannabis.

3. Canopy Growth (CGC) – 30.42%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth rising 30.42% to $10.89 on Wednesday while NASDAQ jumped 0.23% to $16,277.46.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-15.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.56%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Canopy Growth’s EBITDA is 1.8.

More news about Canopy Growth.

4. SNDL Inc. (SNDL) – 22.55%

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

NASDAQ ended the session with SNDL Inc. rising 22.55% to $2.50 on Wednesday, after two successive sessions in a row of gains. NASDAQ jumped 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, SNDL Inc. has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.6%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.1%, now sitting on 900.96M for the twelve trailing months.

Sales Growth

SNDL Inc.’s sales growth for the current quarter is 971.6%.

Moving Average

SNDL Inc.’s worth is way above its 50-day moving average of $1.43 and way above its 200-day moving average of $1.53.

More news about SNDL Inc..

5. Tilray (TLRY) – 18.26%

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

NASDAQ ended the session with Tilray jumping 18.26% to $2.85 on Wednesday, after four sequential sessions in a row of losses. NASDAQ rose 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36%.

Moving Average

Tilray’s value is way higher than its 50-day moving average of $1.93 and way higher than its 200-day moving average of $2.03.

More news about Tilray.

6. First Majestic Silver (AG) – 16.61%

First Majestic Silver Corp. engages in the acquisition, exploration, development, and production of mineral properties with a focus on silver and gold production in North America. Its projects include the San Dimas mine covering an area of approximately 71,867 hectares located in Durango State, Mexico; the Santa Elena that covers an area of approximately 102,244 hectares located in Sonora State, México; and the La Encantada covering an area of approximately 4,076 hectares located in Coahuila State, México. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006. First Majestic Silver Corp. was incorporated in 1979 and is headquartered in Vancouver, Canada.

NYSE ended the session with First Majestic Silver rising 16.61% to $7.51 on Wednesday while NYSE jumped 0.22% to $18,146.64.

Earnings Per Share

As for profitability, First Majestic Silver has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.76%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 7.6%, now sitting on 573.8M for the twelve trailing months.

Volume

Today’s last reported volume for First Majestic Silver is 24137200 which is 217.03% above its average volume of 7613420.

Earnings Before Interest, Taxes, Depreciation, and Amortization

First Majestic Silver’s EBITDA is 173.13.

Moving Average

First Majestic Silver’s value is way higher than its 50-day moving average of $4.96 and way above its 200-day moving average of $5.52.

More news about First Majestic Silver.

7. BP Prudhoe Bay Royalty Trust (BPT) – 16.36%

BP Prudhoe Bay Royalty Trust operates as a grantor trust in the United States. The company holds overriding royalty interest in the Prudhoe Bay oil field located on the North Slope of Alaska. The Prudhoe Bay field extends approximately 12 miles by 27 miles and contains approximately 150,000 gross productive acres. BP Prudhoe Bay Royalty Trust was founded in 1989 and is based in Houston, Texas.

NYSE ended the session with BP Prudhoe Bay Royalty Trust rising 16.36% to $3.14 on Wednesday while NYSE rose 0.22% to $18,146.64.

Earnings Per Share

As for profitability, BP Prudhoe Bay Royalty Trust has a trailing twelve months EPS of $0.26.

PE Ratio

BP Prudhoe Bay Royalty Trust has a trailing twelve months price to earnings ratio of 12.08. Meaning, the purchaser of the share is investing $12.08 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 104.18%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

BP Prudhoe Bay Royalty Trust’s EBITDA is -156.18.

Yearly Top and Bottom Value

BP Prudhoe Bay Royalty Trust’s stock is valued at $3.14 at 17:32 EST, way below its 52-week high of $8.92 and way higher than its 52-week low of $2.00.

More news about BP Prudhoe Bay Royalty Trust.

8. Cronos Group (CRON) – 8.68%

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

NASDAQ ended the session with Cronos Group rising 8.68% to $2.88 on Wednesday while NASDAQ rose 0.23% to $16,277.46.

Earnings Per Share

As for profitability, Cronos Group has a trailing twelve months EPS of $-0.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.3%.

Moving Average

Cronos Group’s worth is way above its 50-day moving average of $2.09 and way above its 200-day moving average of $1.96.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 87.24M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Cronos Group’s EBITDA is -1.17.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Cronos Group’s stock is considered to be oversold (<=20).

More news about Cronos Group.

9. Dell (DELL) – 8.62%

Dell Technologies Inc. designs, develops, manufactures, markets, sells, and supports various comprehensive and integrated solutions, products, and services in the Americas, Europe, the Middle East, Asia, and internationally. The company operates through two segments, Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment provides modern and traditional storage solutions, including all-flash arrays, scale-out file, object platforms, hyper-converged infrastructure, and software-defined storage; and general-purpose and AI-optimized servers. This segment also offers networking products and services comprising wide area network infrastructure, data center and edge networking switches, and cables and optics that help its business customers to transform and modernize their infrastructure, mobilize and enrich end-user experiences, and accelerate business applications and processes; software and peripherals; and consulting, support, and deployment services. The CSG segment provides desktops, workstations, and notebooks; displays, docking stations, keyboards, mice, webcam, and audio devices; and third-party software and peripherals, as well as configuration, support and deployment, and extended warranty services. It is involved in cybersecurity technology-driven security solutions to prevent security breaches, detect malicious activity, respond rapidly when a security breach occurs, and identify emerging threats; originating, collecting, and servicing customer financing arrangements; and the resale of VMware products and services. The company serves enterprises, public institutions, and small and medium-sized businesses through its direct sales channel, value-added resellers, system integrators, distributors, and retailers. The company was formerly known as Denali Holding Inc. and changed its name to Dell Technologies Inc. in August 2016. Dell Technologies Inc. was founded in 1984 and is headquartered in Round Rock, Texas.

NYSE ended the session with Dell jumping 8.62% to $128.65 on Wednesday, after two consecutive sessions in a row of losses. NYSE rose 0.22% to $18,146.64, after two consecutive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Dell has a trailing twelve months EPS of $4.36.

PE Ratio

Dell has a trailing twelve months price to earnings ratio of 29.51. Meaning, the purchaser of the share is investing $29.51 for every dollar of annual earnings.

More news about Dell.

10. Hecla Mining (HL) – 8.55%

Hecla Mining Company, together with its subsidiaries, provides precious and base metal properties in the United States, Canada, Japan, Korea, and China. The company mines for silver, gold, lead, and zinc concentrates, as well as carbon material containing silver and gold for custom smelters, metal traders, and third-party processors; and doré containing silver and gold. It flagship project is the Greens Creek mine located on Admiralty Island in southeast Alaska. Hecla Mining Company was incorporated in 1891 and is headquartered in Coeur d'Alene, Idaho.

NYSE ended the session with Hecla Mining jumping 8.55% to $5.46 on Wednesday, after four successive sessions in a row of gains. NYSE rose 0.22% to $18,146.64, after two successive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Hecla Mining has a trailing twelve months EPS of $-0.14.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.27%.

More news about Hecla Mining.

Losers Today

1. Yield10 Bioscience (YTEN) – -42.57%

Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing high value seed traits for the agriculture and food industries. It also has an oilseed development center in Saskatchewan, Canada. Yield10 Bioscience, Inc. has research agreements with Bayer AG to develop traits in soybean; Forage Genetics International, LLC to develop traits in forage sorghum; J. R. Simplot Company to develop novel traits in potato; and GDM Seeds Inc. to evaluate yield traits in soybeans. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.

NASDAQ ended the session with Yield10 Bioscience sliding 42.57% to $0.22 on Wednesday while NASDAQ rose 0.23% to $16,277.46.

Earnings Per Share

As for profitability, Yield10 Bioscience has a trailing twelve months EPS of $-2.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -380.77%.

Yearly Top and Bottom Value

Yield10 Bioscience ‘s stock is valued at $0.22 at 17:32 EST, way under its 52-week high of $3.29 and way above its 52-week low of $0.18.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Yield10 Bioscience ‘s stock is considered to be overbought (>=80).

Volatility

Yield10 Bioscience ‘s last week, last month’s, and last quarter’s current intraday variation average was a negative 72.73%, a negative 0.81%, and a positive 12.31%.

Yield10 Bioscience ‘s highest amplitude of average volatility was 72.73% (last week), 17.27% (last month), and 12.31% (last quarter).

Moving Average

Yield10 Bioscience ‘s worth is way under its 50-day moving average of $0.28 and way below its 200-day moving average of $0.56.

More news about Yield10 Bioscience .

2. FibroGen (FGEN) – -31.94%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen sliding 31.94% to $1.47 on Wednesday while NASDAQ jumped 0.23% to $16,277.46.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.

More news about FibroGen.

3. Identiv (INVE) – -18.7%

Identiv, Inc., a security technology company, that provides secure identification and physical security solutions that secure things, data, and physical places worldwide. It operates in two segments, Identity and Premises. The Identity segment offers products and solutions that enables secure access to information serving the logical access and cyber security markets, as well as protecting connected objects and information using radio-frequency identification embedded security. The Premises segment provides solutions for premises security market, such as access control, video surveillance, analytics, audio, access readers, and identities to government facilities, schools, utilities, hospitals, stores, and apartment buildings. The company sells its products through dealers, systems integrators, value added resellers, and resellers. The company was formerly known as Identive Group, Inc. and changed its name to Identiv, Inc. in May 2014. Identiv, Inc. was founded in 1990 and is headquartered in Fremont, California.

NASDAQ ended the session with Identiv falling 18.7% to $6.87 on Wednesday, after four consecutive sessions in a row of gains. NASDAQ jumped 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Identiv has a trailing twelve months EPS of $-0.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.77%.

Volume

Today’s last reported volume for Identiv is 401740 which is 528.94% above its average volume of 63875.

Moving Average

Identiv’s value is way under its 50-day moving average of $8.10 and way under its 200-day moving average of $7.76.

Volatility

Identiv’s last week, last month’s, and last quarter’s current intraday variation average was a positive 4.06%, a negative 0.43%, and a positive 2.19%.

Identiv’s highest amplitude of average volatility was 4.06% (last week), 2.71% (last month), and 2.19% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Identiv’s stock is considered to be oversold (<=20).

More news about Identiv.

4. Ulta Beauty (ULTA) – -15.34%

Ulta Beauty, Inc. operate specialty retail stores selling cosmetics, fragrance, haircare and skincare products, and related accessories and services in the United States. It offers broad assortment of branded and private label beauty products including cosmetics, fragrance, haircare, skincare, bath and body products, professional hair products, and salon styling tools; and salon services, including hair, skin, makeup, and brow services, as well as nail services. The company's private label products comprises Ulta Beauty Collection branded cosmetics, skincare, and bath products, as well as Ulta Beauty branded products; and the Ulta Beauty branded gifts. It also distributes its products through its stores, website, and mobile applications. The company was incorporated in 1990 and is based in Bolingbrook, Illinois.

NASDAQ ended the session with Ulta Beauty dropping 15.34% to $439.98 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Ulta Beauty has a trailing twelve months EPS of $26.03.

PE Ratio

Ulta Beauty has a trailing twelve months price to earnings ratio of 16.9. Meaning, the purchaser of the share is investing $16.9 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 62.64%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Ulta Beauty’s EBITDA is 51.12.

Yearly Top and Bottom Value

Ulta Beauty’s stock is valued at $439.98 at 17:32 EST, way below its 52-week high of $563.17 and way above its 52-week low of $368.02.

Moving Average

Ulta Beauty’s worth is way under its 50-day moving average of $510.17 and under its 200-day moving average of $450.59.

More news about Ulta Beauty.

5. Zentalis Pharmaceuticals (ZNTL) – -10.54%

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York.

NASDAQ ended the session with Zentalis Pharmaceuticals falling 10.54% to $14.43 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Zentalis Pharmaceuticals has a trailing twelve months EPS of $-4.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -67.09%.

Yearly Top and Bottom Value

Zentalis Pharmaceuticals’s stock is valued at $14.43 at 17:32 EST, way below its 52-week high of $31.46 and way above its 52-week low of $9.56.

Moving Average

Zentalis Pharmaceuticals’s worth is higher than its 50-day moving average of $13.52 and way under its 200-day moving average of $18.56.

Volume

Today’s last reported volume for Zentalis Pharmaceuticals is 1130240 which is 37.79% above its average volume of 820222.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 28% and 49.2%, respectively.

More news about Zentalis Pharmaceuticals.

6. Nikola (NKLA) – -9.1%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions in the United States and internationally. The company operates in truck and energy units. It commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. In addition, it develops a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. Further, its products include Nikola Tre Class 8 truck and the Nikola's Class 8 FCEV. Additionally, the company assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola sliding 9.1% to $0.89 on Wednesday, after three successive sessions in a row of losses. NASDAQ rose 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -138.82%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 75.7%, now sitting on 35.84M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 65.4% and 50%, respectively.

More news about Nikola.

7. Y-mAbs Therapeutics (YMAB) – -8.83%

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

NASDAQ ended the session with Y-mAbs Therapeutics sliding 8.83% to $14.76 on Wednesday while NASDAQ rose 0.23% to $16,277.46.

Earnings Per Share

As for profitability, Y-mAbs Therapeutics has a trailing twelve months EPS of $-0.49.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.39%.

More news about Y-mAbs Therapeutics.

8. Rumble (RUM) – -8.74%

Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.

NASDAQ ended the session with Rumble sliding 8.74% to $6.68 on Wednesday, after two sequential sessions in a row of gains. NASDAQ jumped 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Rumble has a trailing twelve months EPS of $-0.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.68%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Rumble’s stock is considered to be overbought (>=80).

Moving Average

Rumble’s value is way higher than its 50-day moving average of $5.77 and under its 200-day moving average of $6.69.

More news about Rumble.

9. Intel (INTC) – -8.22%

Intel Corporation designs, develops, manufactures, markets, and sells computing and related products and services worldwide. It operates through Client Computing Group, Data Center and AI, Network and Edge, Mobileye, and Intel Foundry Services segments. The company's products portfolio comprises central processing units and chipsets, system-on-chips (SoCs), and multichip packages; mobile and desktop processors; hardware products comprising graphics processing units (GPUs), domain-specific accelerators, and field programmable gate arrays (FPGAs); and memory and storage, connectivity and networking, and other semiconductor products. It also offers silicon devices and software products; and optimization solutions for workloads, such as AI, cryptography, security, storage, networking, and leverages various features supporting diverse compute environments. In addition, the company develops and deploys advanced driver assistance systems (ADAS), and autonomous driving technologies and solutions; and provides advanced process technologies backed by an ecosystem of IP, EDA, and design services, as well as systems of chips, including advanced packaging technologies, software and accelerate bring-up, and integration of chips and driving standards. Further, it delivers and deploys intelligent edge platforms that allow developers to achieve agility and drive automation using AI for efficient operations with data integrity, as well as provides hardware and software platforms, tools, and ecosystem partnerships for digital transformation from the cloud to edge. The company serves original equipment manufacturers, original design manufacturers, cloud service providers, and other manufacturers and service providers. It has a strategic agreement with Synopsys, Inc. to develop EDA and IP solutions; and ARM that enables chip designers to build optimized compute SoCs on the Intel 18A process. Intel Corporation was incorporated in 1968 and is headquartered in Santa Clara, California.

NASDAQ ended the session with Intel dropping 8.22% to $40.33 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.23% to $16,277.46, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Intel has a trailing twelve months EPS of $0.4.

PE Ratio

Intel has a trailing twelve months price to earnings ratio of 100.83. Meaning, the purchaser of the share is investing $100.83 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.57%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Feb 6, 2024, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 1.14%.

Volatility

Intel’s last week, last month’s, and last quarter’s current intraday variation average was 0.85%, 0.01%, and 1.75%.

Intel’s highest amplitude of average volatility was 0.85% (last week), 2.27% (last month), and 1.75% (last quarter).

More news about Intel.

10. Zhongchao (ZCMD) – -5.97%

Zhongchao Inc. provides healthcare information, education, and training services in China. It offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company operates through its mdmooc.org online platform, as well as Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zhongchao dropping 5.97% to $1.26 on Wednesday while NASDAQ rose 0.23% to $16,277.46.

Earnings Per Share

As for profitability, Zhongchao has a trailing twelve months EPS of $-2.97.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.47%.

More news about Zhongchao.

Stay up to date with our winners and losers daily report